Custom Gene Synthesis Service Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Below 1000 bp, 1001 to 3000 bp, 3001 to 5000 bp, above 5000 bp), By Application (Commercial, Academic Research), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.59 Billion
CAGR (2026-2031)	8.61%
Fastest Growing Segment	Commercial
Largest Market	North America
Market Size (2031)	USD 2.61 Billion

Market Overview

The Global Custom Gene Synthesis Service Market will grow from USD 1.59 Billion in 2025 to USD 2.61 Billion by 2031 at a 8.61% CAGR. Custom gene synthesis services involve the artificial construction of double-stranded DNA molecules de novo, enabling the creation of specific genetic sequences without reliance on natural templates. This technology serves as a foundational element for genetic engineering, facilitating precise modifications in pharmaceutical development, agricultural biotechnology, and academic research. The primary drivers supporting market growth include the accelerating pace of biologics discovery and the critical necessity for synthetic DNA in developing novel vaccines and personalized medicines. According to the American Society of Gene & Cell Therapy, in 2024, the global pipeline included more than 4,000 gene, cell, and RNA therapies in development, illustrating the substantial industrial demand for high-quality synthetic genetic material.

Despite this positive trajectory, the market encounters a significant impediment regarding the synthesis of complex or long DNA sequences. The production of sequences with high GC content or repetitive structures often results in reduced yields and increased error rates using standard chemical methods, which elevates production costs and extends turnaround times. This technical bottleneck restricts the rapid scalability required to satisfy rising industrial needs, potentially impeding broader market expansion as researchers increasingly require intricate and error-free genetic constructs for advanced therapeutic applications.

Key Market Drivers

Accelerated growth of gene and cell therapy development acts as a primary catalyst for the Global Custom Gene Synthesis Service Market. As these advanced modalities transition from early-stage research to commercialization, there is a burgeoning requirement for high-quality, GMP-grade synthetic DNA to manufacture viral vectors, plasmids, and guide RNAs. This surge in therapeutic innovation creates a sustained dependency on synthesis providers to deliver precise genetic constructs at scale, ensuring the availability of critical upstream materials for patient treatments. This trend is substantiated by regulatory milestones; according to the U.S. Food and Drug Administration (FDA), in 2023, the agency approved seven new cell and gene therapies, a record figure that underscores the maturing industrial pipeline and the expanding market need for reliable synthetic genetic components.

Technological advancements in DNA synthesis platforms and automation simultaneously drive market value by overcoming the limitations of traditional phosphoramidite chemistry. Emerging methods, such as enzymatic synthesis and silicon-based automation, enable the rapid production of longer, complex sequences with high fidelity, directly addressing the demand for intricate constructs in biologics discovery. These innovations are attracting substantial capital to scale production capabilities; according to Elegen, in May 2024, the company secured $35 million in Series B financing to expand its proprietary cell-free DNA manufacturing technology. This technological adoption is translating into tangible financial growth for the sector; according to Twist Bioscience, in November 2024, the company reported that its synthetic biology revenue grew to $123.5 million for the fiscal year 2024.

Download Free Sample Report

Key Market Challenges

The synthesis of complex and long DNA sequences presents a significant technical barrier that directly hampers the scalability of the global custom gene synthesis service market. Manufacturers face considerable difficulties when producing sequences characterized by high GC content or intricate repetitive structures, which frequently result in reduced yields and increased error rates. These technical limitations compel service providers to absorb higher production costs and endure extended turnaround times to ensure accuracy, thereby reducing overall operational efficiency. Consequently, the inability to reliably and rapidly deliver these intricate constructs delays the supply chain, preventing vendors from fully capitalizing on the high-volume demands of pharmaceutical and academic clients who require these specific materials for sensitive applications.

This operational bottleneck severely restricts market expansion by creating a disparity between the availability of synthetic DNA and the accelerating pace of therapeutic research. The failure to efficiently scale complex sequence production limits the industry's capacity to support well-funded development programs that depend on prompt material delivery. According to SynBioBeta, in 2024, venture investment in the synthetic biology industry reached 12.2 billion dollars. This substantial magnitude of capital highlights the intense industrial demand for genetic materials, yet the persistent challenges in synthesizing complex sequences effectively constrain the market from realizing its full growth potential in alignment with this investment.

Key Market Trends

The integration of artificial intelligence for sequence optimization is fundamentally reshaping the market by enhancing the design phase of synthetic biology. AI algorithms are increasingly employed to optimize codon usage and predict structural stability before physical synthesis begins, thereby reducing failure rates and accelerating the design-build-test cycle for therapeutic candidates. This computational evolution is stimulating massive demand for synthetic constructs to physically validate algorithmic predictions. According to Xaira Therapeutics, April 2024, in the 'Company Launch Announcement', the firm secured $1 billion in committed capital to advance AI-driven drug discovery, a massive investment that underscores the growing industrial reliance on high-throughput gene synthesis to verify AI-generated protein designs.

Concurrently, the emergence of DNA data storage applications is expanding the market's total addressable landscape beyond traditional life sciences. As global digital data generation outpaces conventional storage capacity, synthetic DNA is being adopted as a durable, high-density medium for long-term archival. This trend is transitioning from theoretical research to commercial reality, creating a new niche for synthesis providers to encoded digital information into genetic code. According to Biomemory, January 2024, in the 'DNA Cards Launch Press Release', the company released the world's first commercially accessible DNA storage product with a capacity of 1 kilobyte, demonstrating the practical feasibility and initial commercialization of this technology for archival purposes.

Segmental Insights

The Commercial segment is recognized as the fastest-growing category in the Global Custom Gene Synthesis Service Market, driven by expanding investments from pharmaceutical and biotechnology companies. These organizations increasingly utilize synthetic DNA to accelerate drug discovery, specifically for antibody development and vaccine research. This demand is reinforced by the need for precise genetic material in developing personalized therapies. Furthermore, supportive guidelines from the U.S. Food and Drug Administration regarding biologics have encouraged private sector innovation, compelling companies to prioritize outsourced synthesis services to maintain scalability and efficiency in their product development pipelines.

Regional Insights

North America commands the Global Custom Gene Synthesis Service Market, driven by a mature biotechnology sector and significant capital allocation toward genomic research. The region hosts a dense network of major service providers and benefits from robust public funding, notably from the National Institutes of Health. This financial and infrastructural support accelerates the adoption of synthetic biology applications, particularly in personalized medicine and vaccine development. Consequently, the combination of strong industrial capabilities and a supportive regulatory framework ensures North America remains the central hub for gene synthesis innovation and commercialization.

Recent Developments

• In August 2024, Twist Bioscience Corporation expanded its synthetic DNA product portfolio by increasing the length capabilities of its Gene Fragments. The company announced that customers could order gene fragments ranging from 1.8 kilobases to 5.0 kilobases, maintaining the same rapid turnaround time starting at two business days. This enhancement allowed researchers to obtain longer, ready-to-use DNA constructs for applications such as protein engineering, pathway engineering, and functional genomics. The expanded offering was compatible with various downstream cloning methods and aimed to streamline workflows by reducing the need for researchers to stitch together shorter fragments or perform additional assembly steps.
• In July 2024, Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments, marking a significant milestone for its proprietary enzymatic DNA synthesis platform. The company became the first to offer the synthesis of complete, contiguous DNA oligonucleotides up to 600 base pairs in length without requiring assembly steps. This product launch followed a successful early access program and aimed to provide researchers with sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments. The enzymatic approach eliminated the limitations associated with traditional chemical synthesis, allowing for the rapid production of complex sequences for various biological applications.
• In June 2024, GenScript Biotech Corporation launched the FLASH Gene service, a new sequence-to-plasmid offering designed to accelerate synthetic biology research. This service enabled the delivery of gene constructs in as few as four business days, addressing the industry's need for rapid turnaround times in the development of antibody drugs, vaccines, and cell therapies. The company implemented a flat-rate pricing model starting at $89, which included gene synthesis, cloning, and plasmid preparation. The service utilized GenScript’s expanded manufacturing facility to ensure high-throughput capacity and guaranteed 100% sequence accuracy for the delivered plasmids, supporting researchers in streamlining their experimental workflows.
• In January 2024, Elegen entered into a strategic collaboration and licensing agreement with GSK to integrate its proprietary cell-free DNA manufacturing technology into the pharmaceutical company’s development of vaccines and medicines. Under the terms of this multi-year deal, GSK committed to providing up to $35 million in near-term financial support, including upfront fees and purchase commitments for Elegen’s ENFINIA DNA. The agreement also outlined potential milestone payments and an option for GSK to make an equity investment in Elegen. This partnership aimed to leverage Elegen's rapid DNA production capabilities to accelerate the discovery and clinical advancement of genetic medicines, including RNA-based therapies.

Key Market Players

• GenScript Biotech Corporation
• Biomatik Corporation
• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies, Inc.
• Synbio Technologies LLC
• Biomol GmbH
• Eurofins Genomics Germany GmbH
• BioCat GmbH
• Azenta US Inc.
• ProMab Biotechnologies, Inc.

By Type	By Application	By Region
Below 1000 bp 1001 to 3000 bp 3001 to 5000 bp above 5000 bp	Commercial Academic Research	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Custom Gene Synthesis Service Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Custom Gene Synthesis Service Market, By Type:

• Below 1000 bp
• 1001 to 3000 bp
• 3001 to 5000 bp
• above 5000 bp

• Custom Gene Synthesis Service Market, By Application:

• Commercial
• Academic Research

• Custom Gene Synthesis Service Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE